NewAmsterdam Pharma Company NV
NAMS37.425USD
+0.425+1.15%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.21BCap. mercado
PérdidaP/E TTM
Más Datos de NewAmsterdam Pharma Company NV Compañía
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Información de NewAmsterdam Pharma Company NV
Símbolo de cotizaciónNAMS
Nombre de la empresaNewAmsterdam Pharma Company NV
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
DirecciónGooimeer 2-35
CiudadNAARDEN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal1411 DC
Teléfono31352062971
Sitio Webhttps://ir.newamsterdampharma.com/
Símbolo de cotizaciónNAMS
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Ejecutivos de NewAmsterdam Pharma Company NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: hace 16 horas
Actualizado: hace 16 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
Otro
51.00%
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
Otro
51.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.22%
Investment Advisor/Hedge Fund
24.29%
Venture Capital
20.51%
Hedge Fund
15.00%
Private Equity
14.76%
Research Firm
1.68%
Family Office
0.74%
Sovereign Wealth Fund
0.44%
Individual Investor
0.44%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
280
119.62M
106.21%
+3.10M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frazier Life Sciences Management, L.P.
16.63M
14.76%
+18.71K
+0.11%
Aug 18, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.52%
--
--
Jun 30, 2025
RA Capital Management, LP
10.14M
9%
--
--
Jun 30, 2025
Forbion Capital Partners
9.32M
8.27%
-1.26M
-11.93%
Sep 26, 2025
Capital World Investors
8.39M
7.45%
+1.59M
+23.37%
Jun 30, 2025
Viking Global Investors LP
6.98M
6.2%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
5.12M
4.54%
+1.01M
+24.66%
Jun 30, 2025
Jennison Associates LLC
2.95M
2.62%
-1.02M
-25.79%
Jun 30, 2025
Wellington Management Company, LLP
3.32M
2.95%
-218.98K
-6.18%
Jun 30, 2025
Adage Capital Management, L.P.
3.01M
2.68%
+1.06M
+54.46%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
ALPS Medical Breakthroughs ETF
1.94%
Global X Guru Index ETF
1.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
First Trust NASDAQ Pharmaceuticals ETF
0.59%
Harbor Health Care ETF
0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.33%
Invesco Nasdaq Biotechnology ETF
0.32%
iShares Biotechnology ETF
0.2%
First Trust IPOX Europe Equity Opportunities ETF
0.15%
Ver más
ALPS Medical Breakthroughs ETF
Proporción1.94%
Global X Guru Index ETF
Proporción1.39%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.98%
First Trust NASDAQ Pharmaceuticals ETF
Proporción0.59%
Harbor Health Care ETF
Proporción0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.41%
ProShares Ultra Nasdaq Biotechnology
Proporción0.33%
Invesco Nasdaq Biotechnology ETF
Proporción0.32%
iShares Biotechnology ETF
Proporción0.2%
First Trust IPOX Europe Equity Opportunities ETF
Proporción0.15%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
